BONE GROWTH

Ascendis Pharma · Navepegritide · TransCon CNP

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

SOURCE: Investors.AscendisPharma.com COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial…

Read More New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
Achondroplasia · Vosoritide

Health Ministry announces introduction of Achondroplasia drug for children patients

SOURCE: AGENDA.GE Agenda.ge, 14 Nov 2023 – 15:18, Tbilisi,Georgia Vosoritide, a medication used for the treatment of achondroplasia among children patients, is now available in Georgia, the country’s Ministry of…

Read More Health Ministry announces introduction of Achondroplasia drug for children patients
BioMarin

BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational,…

Read More BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

translate ?